Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Addition of Sorafenib to G-CSF, Cladribine, Cytarabine and Mitoxantrone (G-CLAM) in Adults With Newly-Diagnosed Acute Myeloid Leukemia (AML) Independent of FLT3-ITD Status: A Phase 1/2 Study

NCT02728050 is registered in ClinicalTrials.gov with University of Washington as lead sponsor.

NCT NCT02728050
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02728050 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Addition of Sorafenib to G-CSF, Cladribine, Cytarabine and Mitoxantrone (G-CLAM) in Adults With Newly-Diagnosed Acute Myeloid Leukemia (AML) Independent of FLT3-ITD Status: A Phase 1/2 Study
Lead sponsor
University of Washington
Phase
Phase 1/2
Overall status
Completed
Start date
December 1, 2016
Completion date
April 4, 2023
Enrollment
84 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute biphenotypic leukemia, acute myeloid leukemia, de novo myelodysplastic syndrome, myelodysplastic syndrome, myeloproliferative neoplasm